Goldman Sachs
AGMB

Goldman Sachs’s AgomAb Therapeutics NV AGMB Stock Holding History

Goldman Sachs’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Sell
11,800
-23,939
-67% -$269K ﹤0.01% 6264
2026
Q1 		$375K Buy
+35,739
New +$506K ﹤0.01% 5769

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs's AGMB Position: Q2 2026 in Review

Goldman Sachs reduced its AgomAb Therapeutics NV (AGMB) stake by 67% in Q2 2026, selling an estimated $269K and leaving 11,800 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #6264.

Goldman Sachs first reported a position in AGMB in Q1 2026 and has held it in 2 quarters since. The position peaked at $375K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Goldman Sachs held 11,800 shares of AgomAb Therapeutics NV worth $153K as of Q2 2026.
  • Goldman Sachs sold 23,939 AgomAb Therapeutics NV shares in Q2 2026, an estimated $269K.
  • AgomAb Therapeutics NV made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6264 holding.
  • Goldman Sachs first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 2 quarters since.
  • Goldman Sachs's AgomAb Therapeutics NV position peaked at $375K in Q1 2026.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.